Cytovia Therapeutics Email Formats
Biotechnology Research • 
18851 NE 29th Ave, 2nd floor, United States • 11-20 Employees
Cytovia Therapeutics Email Formats
Cytovia Therapeutics uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
Key Contact at Cytovia Therapeutics
Hao Chang
Senior Director, Preclinical Research
Company overview
| Headquarters | 18851 NE 29th Ave, 2nd floor, Aventura, Florida 33180, US |
| Phone number | +17865917001 |
| Website | |
| NAICS | 541714 |
| Employees | 11-20 |
| Socials |
About Cytovia Therapeutics
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. We are developing three types of iPSC-derived Natural Killer cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multispecific antibody platform designed to engage natural killer cells by targeting NKp46 using a proprietary Flex-NK™ technology. These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Clinical studies are expected to initiate in 2022. Cytovia’s R&D laboratories in Natick, MA and GMP cell manufacturing facility in Puerto Rico are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF). Cytovia Therapeutics has recently formed CytoLynx Therapeutics, a joint-venture entity focused on research and development, manufacturing, and commercialization activities in Greater China and beyond. Find out more at www.cytoviatx.com.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Cytovia Therapeutics has 2 employees across 2 departments.
Departments
Number of employees
Cytovia Therapeutics Tech Stack
Discover the technologies and tools that power Cytovia Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Issue trackers
Appointment scheduling
Blogs
Miscellaneous
Security
Miscellaneous
JavaScript frameworks
IaaS
CDN
Reverse proxies
Miscellaneous
Spain
Switzerland
Italy
Germany
Frequently asked questions
4.8
40,000 users
